Prévisions du marché de l\'épilepsie en Amérique du Sud et en Amérique centrale jusqu\'en 2030 - Analyse régionale - par type (épilepsie myoclonique progressive, épilepsie réflexe, épilepsie généralisée et autres), voie d\'administration (orale, parentérale et autres), type de traitement (médicaments de première génération, médicaments de deuxième génération et médicaments de troisième génération), groupe d\'âge (adultes et enfants) et canal de distribution (pharmacies hospitalières, pharmacies de détail et autres)
L\'augmentation des programmes de sensibilisation menés par des organisations alimente le marché de l\'épilepsie en Amérique du Sud et en Amérique centrale
La sensibilisation croissante à l\'épilepsie, à ses symptômes et à l\'importance d\'un diagnostic précoce a entraîné une augmentation du nombre de patients demandant des soins médicaux. Des organisations telles que l\'Epilepsy Foundation, l\'Epilepsy Society, l\'American Epilepsy Society et l\'Epilepsy Association of Central Florida jouent un rôle crucial dans l\'éducation des gens sur cette maladie. L\'implication de ces organisations a entraîné une augmentation des taux de diagnostic et une population de patients plus large nécessitant un traitement contre l\'épilepsie. De nombreuses campagnes de sensibilisation sont menées par des organisations du monde entier pour faire connaître cette maladie et les traitements disponibles. Au Brésil, la Ligue brésilienne de l\'épilepsie (LBE) mène des campagnes de sensibilisation à l\'échelle nationale pendant le mois de sensibilisation à l\'épilepsie. Elle organise des événements, distribue du matériel pédagogique et collabore avec les médias pour sensibiliser à l\'épilepsie et réduire la stigmatisation. Ainsi, de telles initiatives et campagnes de sensibilisation entraînent une augmentation des diagnostics et des traitements de l\'épilepsie, offrant des opportunités de croissance lucratives au marché.
Aperçu du marché de l\'épilepsie en Amérique du Sud et en Amérique centrale
Le marché de l\'épilepsie en Amérique du Sud et en Amérique centrale comprend une analyse au niveau des pays du Brésil, de l\'Argentine et du reste de l\'Amérique du Sud et de l\'Amérique centrale. Le Brésil devrait détenir une part de marché importante dans cette région. Selon l\'Organisation panaméricaine de la santé, il existe un écart de traitement en Amérique latine, en Amérique du Sud et dans les Caraïbes, soit plus de 50 %. Ces dernières années, les pays ont renforcé leur concentration sur les maladies non transmissibles, dont l\'épilepsie. Selon l\'article de l\'International Journal of Public Health publié en 2023, un total de 1 375 066 années de vie corrigées de l\'incapacité (DALY) dans les pays d\'Amérique du Sud et d\'Amérique centrale ont été attribuées à l\'épilepsie en 2019, les hommes étant plus touchés.
Chiffre d\'affaires et prévisions du marché de l\'épilepsie en Amérique du Sud et en Amérique centrale jusqu\'en 2030 (en millions de dollars américains)
Segmentation du marché de l\'épilepsie en Amérique du Sud et en Amérique centrale
Le marché de l\'épilepsie en Amérique du Sud et en Amérique centrale est classé en type, voie d\'administration, type de traitement, groupe d\'âge, canal de distribution et pays.
En fonction du type, le marché de l\'épilepsie en Amérique du Sud et en Amérique centrale est classé en épilepsie myoclonique progressive, épilepsie réflexe, épilepsie généralisée et autres. Le segment de l\'épilepsie généralisée détenait la plus grande part de marché en 2022.
En termes de voie d\'administration, le marché de l\'épilepsie en Amérique du Sud et en Amérique centrale est classé en voie orale, parentérale et autres. Français Le segment oral détenait la plus grande part de marché en 2022.
Par type de traitement, le marché de l\'épilepsie d\'Amérique du Sud et centrale est segmenté en médicaments de première génération, médicaments de deuxième génération et médicaments de troisième génération. Le segment des médicaments de troisième génération détenait la plus grande part de marché en 2022.
En fonction du groupe d\'âge, le marché de l\'épilepsie d\'Amérique du Sud et centrale est divisé en adultes et enfants. Le segment des adultes détenait une part de marché plus importante en 2022.
En termes de canal de distribution, le marché de l\'épilepsie d\'Amérique du Sud et centrale est classé en pharmacies hospitalières, pharmacies de détail et autres. Le segment des pharmacies hospitalières détenait la plus grande part de marché en 2022.
Par pays, le marché de l\'épilepsie d\'Amérique du Sud et centrale est segmenté en Brésil, Argentine et reste de l\'Amérique du Sud et centrale. Le Brésil a dominé la part de marché de l\'épilepsie en Amérique du Sud et en Amérique centrale en 2022.
Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc et H. Lundbeck AS sont quelques-unes des principales sociétés opérant sur le marché de l\'épilepsie en Amérique du Sud et en Amérique centrale.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels for Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. South & Central America Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - South & Central America Analysis
6.1 South & Central America: Epilepsy Market
7. South & Central America Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. South & Central America Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. South & Central America Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. South & Central America Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. South & Central America Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. South & Central America Epilepsy Market - Country Analysis
12.1 South & Central America Epilepsy Market Overview
12.1.1 South & Central America: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
12.1.1.1 Brazil: Epilepsy Market Overview
12.1.1.2 Brazil: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 Brazil: Epilepsy Market Breakdown, by Type
12.1.1.2.2 Brazil: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 Brazil: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 Brazil: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 Brazil: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.3 Argentina: Epilepsy Market Overview
12.1.1.4 Argentina: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.4.1 Argentina: Epilepsy Market Breakdown, by Type
12.1.1.4.2 Argentina: Epilepsy Market Breakdown, by Route of Administration
12.1.1.4.3 Argentina: Epilepsy Market Breakdown, by Treatment Type
12.1.1.4.4 Argentina: Epilepsy Market Breakdown, by Age Group
12.1.1.4.5 Argentina: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.5 Rest of South & Central America: Epilepsy Market Overview
12.1.1.6 Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.6.1 Rest of South & Central America: Epilepsy Market Breakdown, by Type
12.1.1.6.2 Rest of South & Central America: Epilepsy Market Breakdown, by Route of Administration
12.1.1.6.3 Rest of South & Central America: Epilepsy Market Breakdown, by Treatment Type
12.1.1.6.4 Rest of South & Central America: Epilepsy Market Breakdown, by Age Group
12.1.1.6.5 Rest of South & Central America: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 LivaNova Plc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Medtronic Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 GSK Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 H. Lundbeck AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. Appendix
15.1 About The Insight Partners
List of Tables
Table 1. South & Central America Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Target Types Overview
Table 11. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 12. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 13. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 14. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 15. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 17. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 19. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 20. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 21. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 23. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 24. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 25. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 26. Recent Organic Growth Strategies in Epilepsy Market
Table 27. Recent Inorganic Growth Strategies in the Epilepsy Market
?
List of Figures
Figure 1. South & Central America Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. South & Central America: Epilepsy Market, By Key Country - Revenue (2022) (US$ Million)
Figure 26. South & Central America: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Brazil: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Argentina: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. Rest of South & Central America: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Growth Strategies in Epilepsy Market
?
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the South & Central America epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.